Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22138855 | 1.00 | HRH3 (0.55) | HRH3EPHX2GPR119GRIN1GRIN2B | |
| SCHEMBL28668218 | 1.00 | HRH3 (0.55) | HRH3EPHX2GPR119GRIN1GRIN2B | |
| SCHEMBL31003122 | 0.92 | HRH3 (0.42) | HRH3GPR119 | |
| SCHEMBL5024491 | 0.85 | HRH3 (0.71) | HRH3EPHX2GPR119FPR2PROKR1 | |
| SCHEMBL22138868 | 0.85 | HRH3 (0.71) | HRH3EPHX2GPR119FPR2PROKR1 | |
| SCHEMBL21606953 | 0.84 | HRH1 (0.49) | HRH3 | |
| SCHEMBL2585740 | 0.84 | HRH3 (0.46) | HRH3 | |
| SCHEMBL2584697 | 0.84 | HRH3 (0.46) | HRH3 | |
| SCHEMBL29601203 | 0.81 | CHEK1 (0.53) | HRH3 | |
| SCHEMBL30826879 | 0.79 | CYP19A1 (0.63) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. (US) | 2025-12-25 | — | — | US | disclosed |
| CN-113766914-B | Pentaneamidine analogues and uses thereof | 美商奥润沙公司 | 2024-02-13 | — | — | CN | disclosed |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | AURANSA INC. | 2022-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388542-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | MALT1, SLC38A7, SLC7A1 | HRH3 474/4885EPHX2 4280/4885GPR119 1064/4885 |
| US-20220144776-A1 | ANALOGUES OF PENTAMIDINE AND USES THEREFOR | DPYD, TYMP, GOT1 | HRH3 2911/4885EPHX2 4438/4885GPR119 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.